Characterization of G9a target genes by whole transcriptome analysis and the resultant changes in the histone methylation status monitored by chromatin immunoprecipitation (ChIP) in the setting of tumor hypoxia and pharmacologic inhibition will play a central role in assessing the therapeutic value. The gene discussed is EHMT2; the disease is neoplasm.